Oxehealth, the global leader in intelligent patient monitoring for acute mental health, has announced FDA and EU clearances of new sleep monitoring software, extending the scope of its contactless patient monitoring platform.
The technology is the latest breakthrough medical device launched by Oxehealth, It assesses patients' sleep/wake patterns with a level of accuracy comparable to polysomnography and provides automated daily outputs which healthcare staff can use to support clinical decision-making.
Given the proven links between sleep and mental health, sleep insights should be a key part of providing the best care and treatment. But until now, obtaining objective and accurate sleep data in acute mental health has been a challenge.
Dr. Michael Geonevese said: "In inpatient psychiatric settings it is impractical and unsafe to attach standard polysomnography equipment to patients.
"Oxehealth's novel solution has such huge potential. The insights it provides can support clinical teams to tailor their care plans and promote recovery.
“Ultimately it could even allow clinical teams to refine medication prescriptions and optimize length of stay." CEO of Oxehealth, Todd Haedrich, commented: "We are excited to announce our latest world-first breakthrough.
“We are now actively seeking acute mental health providers, who are forward thinking and interested in leveraging technology to advance their capabilities, to join our new Innovator Program."
